Date	Period	Revenue/Estimate	Earnings Call
--	2026/Q1	-- / 72.500B	--
--	2025/Q4	-- / 80.232B	--
Feb 6, 2025	2025/Q3	76.369B / 75.285B	--
Nov 7, 2024	2025/Q2	71.633B / 74.047B	--
Aug 6, 2024	2025/Q1	74.771B / 73.939B	--

DatePeriodRevenue/EstimateEarnings Call

--2026/Q1-- / 72.500B--

--2025/Q4-- / 80.232B--

Feb 6, 20252025/Q376.369B / 75.285B--

Nov 7, 20242025/Q271.633B / 74.047B--

Aug 6, 20242025/Q174.771B / 73.939B--

Unlock Free Earnings Estimates

Open Account

Santen Pharmaceutical: Notice regarding revisions to dividend forecasts

Feb 6 01:00 ET

Santen Pharmaceutical: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2025 [IFRS] (consolidated)

Feb 6 01:00 ET

Santen Pharmaceutical: Confirmation letter

Nov 11, 2024 01:32 ET

Santen Pharmaceutical: Half-Yearly Report - Term 113 (2024/04/01 - 2025/03/31)

Nov 11, 2024 01:30 ET

Symbol Price % Chg

See the daily top gainer.

Analysis

Updated: Feb 6, 2025

Buy

No Data